HBeAg levels at week 24 predict response to 8 years of tenofovir in HBeAg-positive chronic hepatitis B patients.
Identifieur interne : 000268 ( PubMed/Corpus ); précédent : 000267; suivant : 000269HBeAg levels at week 24 predict response to 8 years of tenofovir in HBeAg-positive chronic hepatitis B patients.
Auteurs : D. Wong ; M. Littlejohn ; L. Yuen ; K. Jackson ; H. Mason ; J. Bayliss ; G. Rosenberg ; A. Gaggar ; K. Kitrinos ; M. Subramanian ; P. Marcellin ; M. Buti ; H L A. Janssen ; E. Gane ; S. Locarnini ; A. Thompson ; P A RevillSource :
- Alimentary pharmacology & therapeutics [ 1365-2036 ] ; 2017.
Abstract
Hepatitis B e antigen (HBeAg) seroconversion is a treatment endpoint for HBeAg-positive CHB, and a necessary precursor to HBsAg loss. Biomarkers that predict serological outcomes would be useful.
DOI: 10.1111/apt.14362
PubMed: 29023803
Links to Exploration step
pubmed:29023803Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">HBeAg levels at week 24 predict response to 8 years of tenofovir in HBeAg-positive chronic hepatitis B patients.</title><author><name sortKey="Wong, D" sort="Wong, D" uniqKey="Wong D" first="D" last="Wong">D. Wong</name><affiliation><nlm:affiliation>Division of Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Littlejohn, M" sort="Littlejohn, M" uniqKey="Littlejohn M" first="M" last="Littlejohn">M. Littlejohn</name><affiliation><nlm:affiliation>Division of Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Yuen, L" sort="Yuen, L" uniqKey="Yuen L" first="L" last="Yuen">L. Yuen</name><affiliation><nlm:affiliation>Division of Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Jackson, K" sort="Jackson, K" uniqKey="Jackson K" first="K" last="Jackson">K. Jackson</name><affiliation><nlm:affiliation>Division of Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Mason, H" sort="Mason, H" uniqKey="Mason H" first="H" last="Mason">H. Mason</name><affiliation><nlm:affiliation>Division of Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Bayliss, J" sort="Bayliss, J" uniqKey="Bayliss J" first="J" last="Bayliss">J. Bayliss</name><affiliation><nlm:affiliation>Division of Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Rosenberg, G" sort="Rosenberg, G" uniqKey="Rosenberg G" first="G" last="Rosenberg">G. Rosenberg</name><affiliation><nlm:affiliation>Division of Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Gaggar, A" sort="Gaggar, A" uniqKey="Gaggar A" first="A" last="Gaggar">A. Gaggar</name><affiliation><nlm:affiliation>Gilead Sciences, Foster City, CA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Kitrinos, K" sort="Kitrinos, K" uniqKey="Kitrinos K" first="K" last="Kitrinos">K. Kitrinos</name><affiliation><nlm:affiliation>Gilead Sciences, Foster City, CA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Subramanian, M" sort="Subramanian, M" uniqKey="Subramanian M" first="M" last="Subramanian">M. Subramanian</name><affiliation><nlm:affiliation>Gilead Sciences, Foster City, CA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Marcellin, P" sort="Marcellin, P" uniqKey="Marcellin P" first="P" last="Marcellin">P. Marcellin</name><affiliation><nlm:affiliation>Hôpital Beaujon, University of Paris, Clichy, France.</nlm:affiliation></affiliation></author><author><name sortKey="Buti, M" sort="Buti, M" uniqKey="Buti M" first="M" last="Buti">M. Buti</name><affiliation><nlm:affiliation>Liver Unit, Vall d'Hebron (Ciberehd) University Hospital, Barcelona, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Janssen, H L A" sort="Janssen, H L A" uniqKey="Janssen H" first="H L A" last="Janssen">H L A. Janssen</name><affiliation><nlm:affiliation>Toronto Center for Liver Diseases, Toronto Western and General Hospital, University Health Network, University of Toronto, Toronto, ON, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Gane, E" sort="Gane, E" uniqKey="Gane E" first="E" last="Gane">E. Gane</name><affiliation><nlm:affiliation>New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand.</nlm:affiliation></affiliation></author><author><name sortKey="Locarnini, S" sort="Locarnini, S" uniqKey="Locarnini S" first="S" last="Locarnini">S. Locarnini</name><affiliation><nlm:affiliation>Division of Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Thompson, A" sort="Thompson, A" uniqKey="Thompson A" first="A" last="Thompson">A. Thompson</name><affiliation><nlm:affiliation>Department of Gastroenterology, St. Vincent's Hospital, Melbourne, Vic., Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Revill, P A" sort="Revill, P A" uniqKey="Revill P" first="P A" last="Revill">P A Revill</name><affiliation><nlm:affiliation>Division of Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:29023803</idno><idno type="pmid">29023803</idno><idno type="doi">10.1111/apt.14362</idno><idno type="wicri:Area/PubMed/Corpus">000268</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000268</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">HBeAg levels at week 24 predict response to 8 years of tenofovir in HBeAg-positive chronic hepatitis B patients.</title><author><name sortKey="Wong, D" sort="Wong, D" uniqKey="Wong D" first="D" last="Wong">D. Wong</name><affiliation><nlm:affiliation>Division of Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Littlejohn, M" sort="Littlejohn, M" uniqKey="Littlejohn M" first="M" last="Littlejohn">M. Littlejohn</name><affiliation><nlm:affiliation>Division of Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Yuen, L" sort="Yuen, L" uniqKey="Yuen L" first="L" last="Yuen">L. Yuen</name><affiliation><nlm:affiliation>Division of Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Jackson, K" sort="Jackson, K" uniqKey="Jackson K" first="K" last="Jackson">K. Jackson</name><affiliation><nlm:affiliation>Division of Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Mason, H" sort="Mason, H" uniqKey="Mason H" first="H" last="Mason">H. Mason</name><affiliation><nlm:affiliation>Division of Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Bayliss, J" sort="Bayliss, J" uniqKey="Bayliss J" first="J" last="Bayliss">J. Bayliss</name><affiliation><nlm:affiliation>Division of Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Rosenberg, G" sort="Rosenberg, G" uniqKey="Rosenberg G" first="G" last="Rosenberg">G. Rosenberg</name><affiliation><nlm:affiliation>Division of Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Gaggar, A" sort="Gaggar, A" uniqKey="Gaggar A" first="A" last="Gaggar">A. Gaggar</name><affiliation><nlm:affiliation>Gilead Sciences, Foster City, CA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Kitrinos, K" sort="Kitrinos, K" uniqKey="Kitrinos K" first="K" last="Kitrinos">K. Kitrinos</name><affiliation><nlm:affiliation>Gilead Sciences, Foster City, CA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Subramanian, M" sort="Subramanian, M" uniqKey="Subramanian M" first="M" last="Subramanian">M. Subramanian</name><affiliation><nlm:affiliation>Gilead Sciences, Foster City, CA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Marcellin, P" sort="Marcellin, P" uniqKey="Marcellin P" first="P" last="Marcellin">P. Marcellin</name><affiliation><nlm:affiliation>Hôpital Beaujon, University of Paris, Clichy, France.</nlm:affiliation></affiliation></author><author><name sortKey="Buti, M" sort="Buti, M" uniqKey="Buti M" first="M" last="Buti">M. Buti</name><affiliation><nlm:affiliation>Liver Unit, Vall d'Hebron (Ciberehd) University Hospital, Barcelona, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Janssen, H L A" sort="Janssen, H L A" uniqKey="Janssen H" first="H L A" last="Janssen">H L A. Janssen</name><affiliation><nlm:affiliation>Toronto Center for Liver Diseases, Toronto Western and General Hospital, University Health Network, University of Toronto, Toronto, ON, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Gane, E" sort="Gane, E" uniqKey="Gane E" first="E" last="Gane">E. Gane</name><affiliation><nlm:affiliation>New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand.</nlm:affiliation></affiliation></author><author><name sortKey="Locarnini, S" sort="Locarnini, S" uniqKey="Locarnini S" first="S" last="Locarnini">S. Locarnini</name><affiliation><nlm:affiliation>Division of Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Thompson, A" sort="Thompson, A" uniqKey="Thompson A" first="A" last="Thompson">A. Thompson</name><affiliation><nlm:affiliation>Department of Gastroenterology, St. Vincent's Hospital, Melbourne, Vic., Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Revill, P A" sort="Revill, P A" uniqKey="Revill P" first="P A" last="Revill">P A Revill</name><affiliation><nlm:affiliation>Division of Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Alimentary pharmacology & therapeutics</title><idno type="eISSN">1365-2036</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Hepatitis B e antigen (HBeAg) seroconversion is a treatment endpoint for HBeAg-positive CHB, and a necessary precursor to HBsAg loss. Biomarkers that predict serological outcomes would be useful.</div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">29023803</PMID><DateCreated><Year>2017</Year><Month>10</Month><Day>12</Day></DateCreated><DateRevised><Year>2017</Year><Month>10</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2036</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2017</Year><Month>Oct</Month><Day>11</Day></PubDate></JournalIssue><Title>Alimentary pharmacology & therapeutics</Title><ISOAbbreviation>Aliment. Pharmacol. Ther.</ISOAbbreviation></Journal><ArticleTitle>HBeAg levels at week 24 predict response to 8 years of tenofovir in HBeAg-positive chronic hepatitis B patients.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1111/apt.14362</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Hepatitis B e antigen (HBeAg) seroconversion is a treatment endpoint for HBeAg-positive CHB, and a necessary precursor to HBsAg loss. Biomarkers that predict serological outcomes would be useful.</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To evaluate the utility of measuring HBeAg levels for predicting HBeAg seroconversion and HBsAg loss under long-term tenofovir (TDF) therapy.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A total of 266 patients were enrolled into a phase III study of TDF vs adefovir (ADV) for 48 weeks in HBeAg-positive patients, followed by open-label TDF up to 384 weeks. Serum HBeAg levels were measured for subjects with samples available at both baseline and week 24 of treatment (n = 200). Analysis compared subjects who achieved HBeAg seroconversion by week 384 vs no HBeAg seroconversion.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">HBeAg seroconversion rate was 52% by week 384. Time to HBeAg seroconversion was 80 weeks (IQR: 36-162). HBeAg decline at week 24 was associated with HBeAg seroconversion (1.63 vs 0.90 log10 PEIU/mL, P = .002). The optimal threshold for identifying HBeAg seroconversion was HBeAg decline ≥2.2 log10 PEIU/mL at week 24, with HBeAg seroconversion achieved by 76% of patients, compared to 44% if HBeAg decline <2.2 log10 (P < .0001). HBeAg decline ≥2.2 log10 PEIU/mL at week 24 was associated with HBsAg loss in genotype A or D patients (38% vs 15%, P = .03). Precore/basal core promotor variants were associated with lower baseline HBeAg levels, but not HBeAg seroconversion.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Decline in HBeAg levels by week 24 was associated with HBeAg seroconversion and HBsAg loss in HBeAg-positive chronic hepatitis B patients treated with long-term TDF.</AbstractText><CopyrightInformation>© 2017 John Wiley & Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>D</ForeName><Initials>D</Initials><Identifier Source="ORCID">http://orcid.org/0000-0003-1490-0547</Identifier><AffiliationInfo><Affiliation>Division of Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Gastroenterology, St. Vincent's Hospital, Melbourne, Vic., Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Littlejohn</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuen</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jackson</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mason</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bayliss</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosenberg</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaggar</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Gilead Sciences, Foster City, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kitrinos</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Gilead Sciences, Foster City, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Subramanian</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Gilead Sciences, Foster City, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marcellin</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Hôpital Beaujon, University of Paris, Clichy, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buti</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Liver Unit, Vall d'Hebron (Ciberehd) University Hospital, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Janssen</LastName><ForeName>H L A</ForeName><Initials>HLA</Initials><AffiliationInfo><Affiliation>Toronto Center for Liver Diseases, Toronto Western and General Hospital, University Health Network, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gane</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Locarnini</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, St. Vincent's Hospital, Melbourne, Vic., Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Revill</LastName><ForeName>P A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Division of Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>10</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Aliment Pharmacol Ther</MedlineTA><NlmUniqueID>8707234</NlmUniqueID><ISSNLinking>0269-2813</ISSNLinking></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>08</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>09</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>09</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>10</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>10</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>10</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29023803</ArticleId><ArticleId IdType="doi">10.1111/apt.14362</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000268 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000268 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:29023803
|texte= HBeAg levels at week 24 predict response to 8 years of tenofovir in HBeAg-positive chronic hepatitis B patients.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:29023803" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |